BRANFORD, Conn., Dec. 1, 2017 /PRNewswire-USNewswire/ --IsoPlexis Corporation (IsoPlexis), a privately held life sciences company at the forefront of single-cell analytics technology and the immune-based cancer treatment revolution, announced today that the IsoCode Chip, its next-generation technology capable of identifying and predicting patient responses to immunotherapy, was recognized as the top innovation of 2017 by The Scientist.
The IsoCode Chip, used on the IsoLight Platform, provides a simple, integrated solution for detecting cellular responses at the single-cell resolution, in order to better understand how to develop potent personalized therapies. The system can capture a previously unseen 42 different secreted functional proteins per cell, across thousands of single cells simultaneously, and IsoPlexis' bioinformatics tools enable researchers to generate a precise functional patient profile to help predict and understand complex patient response to cancer immunotherapies.
"IsoPlexis is honored to have the IsoCode Chip recognized by The Scientist as the top innovation of 2017," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "Through collaborations with leading academic research centers and biopharmaceutical companies, we are using IsoPlexis' technology advances to improve the development of complex, personalized treatments for highest need cancer patients."
For the past decade, The Scientist has canvassed the life sciences community to identify the latest and greatest tools, technologies and techniques that are having the biggest impact on research. A carefully selected panel of expert, independent judges rank the innovations according to their potential to foster rapid advances or address specific problems in their respective fields. Each year, the 10 products that rate the highest are ranked and featured in The Scientist's December issue.
"Being named The Scientist's No. 1 innovation of 2017 is another validation of the IsoPlexis technology's role in utilizing our immune system to fight cancer," said Rong Fan, Ph.D., IsoPlexis Co-Founder and Scientific Advisory Board Chair, and an Associate Professor of Biomedical Engineering at Yale University. "IsoPlexis' technology is helping researchers capture and understand large quantities of highly precise data, which will lead to more potent immunotherapies for more patients."
James Heath, Ph.D., IsoPlexis Board and Scientific Advisory Board Member and the Elizabeth W. Gilloon Professor of Chemistry at Caltech, said, "Data-driven and highly-targeted immunotherapies are the future of the fight against cancer, and a core focus of my research," adding, "The IsoCode Chip is an important tool to better understand cellular responses in immuno-oncology, and to use that information to improve diagnoses and administration of these powerful therapies."
For more information about The Scientist's 2017 Top 10 Innovations and the full list of winners, visit: https://www.the-scientist.com/2017Top10.
IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer. Using a next-generation diagnostic and therapeutic platform to identify patient responses at the single cell level, IsoPlexis' original scientific leaders from Yale, Caltech, UCLA, and Memorial Sloan Kettering Cancer Center have advanced understandings of personalized therapies against various cancers. IsoPlexis is venture funded by Spring Mountain Capital, North Sound Ventures and Connecticut Innovations, as well as supported through grant funding from the National Cancer Institute and the National Institutes of Health. For additional information on IsoPlexis, visit http://www.isoplexis.com or email email@example.com.
SOURCE IsoPlexis Corporation